Back

Scynexis shares jump 10% after securing BARDA contract worth up to $214 million

Verifying
  • Scynexis secured a BARDA contract to advance oral and intravenous SCY-247.
  • The agreement is worth up to $214 million, including approximately $18.5 million initially.
  • Scynexis completed intravenous Phase 1 dosing, with analysis ongoing after positive oral data.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.